secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2022-08-18T23:59:59+00:00
Accession:  0001193125-22-224202
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme issues $720M 1.00% convertible notes due 2028; repays term loan, buys back shares
--------------------------------------------------------------------------------

- Issued $720M in 1.00% Convertible Senior Notes due 2028, including $95M from over-allotment option.
- Net proceeds ~$701.4M; used to repay $250M term loan, exchange $77.6M of existing notes, and repurchase $90M of common stock.
- Initial conversion price ~$56.02 per share; capped call transactions limit dilution with cap price $75.4075.
- Increased 2022 stock repurchase authorization to $200M (from $100M) to commence after offering close.
- Capped call transactions entered with multiple counterparties to reduce dilution upon conversion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/0001193125-22-224202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-224202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer